Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a vote on extending ACA tax credits, and new collaboration and merger activity highlights continued dealmaking momentum across biopharma.
2m Dec 18, 2025
2m
Pharmaceutical Executive Daily: FDA's Approval of Lerochol
In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals spanning Alzheimer’s disease and B-cell depletion, and the agency issues a national priority voucher tied to Tecvayli in multiple myeloma.
2m Dec 17, 2025
2m
Pharmaceutical Executive Daily: TrumpRx's Critical Blind Spot
In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher tied to Tecvayli in multiple myeloma, and Sobi announces a $1.5 billion agreement to acquire a gout therapy.
2m Dec 16, 2025
2m
Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.
2m Dec 15, 2025
2m
Pharmaceutical Executive Daily: FDA's Approval of Waskyra
In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.
2m Dec 11, 2025
2m
Pharmaceutical Executive Daily: FDA's New Standard for CAR-T Approvals
In today’s Pharmaceutical Executive Daily, the FDA introduces a new superiority standard for future CAR-T approvals, Relation Therapeutics and Novartis form a $1 billion multi-program collaboration targeting atopic diseases, and new insights reveal how payers are shaping expectations for Phase III trial design.
2m Dec 10, 2025
2m
Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions
In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data show sustained remissions with Carvykti in relapsed or refractory multiple myeloma, and Pfizer signs an exclusive collaboration with Yao Pharma to advance oral small-molecule GLP-1 agonists.
2m Dec 09, 2025
2m
Pharmaceutical Executive Daily: FDA Approves Breyanzi
In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met its primary endpoint in a head-to-head Phase III trial against Imbruvica for CLL/SLL, and new analyses highlight how health systems are strengthening partnerships to support cell and gene therapy commercialization.
2m Dec 08, 2025
2m
Pharmaceutical Executive Daily: Mark Cuban's Push for Generic Drug Fee Waivers
In today’s Pharmaceutical Executive Daily, former FDA commissioners caution that new vaccine policies could weaken long-established regulatory standards, Mark Cuban urges federal officials to waive fees to boost generic drug competition, and a new report reveals patients are increasingly avoiding care due to rising healthcare costs.
2m Dec 05, 2025
2m
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
In today’s Pharmaceutical Executive Daily, the FDA appoints Tracy Beth Høeg as acting CDER director, health systems explore new commercialization partnerships for cell and gene therapies, and Aidoc submits a breakthrough-designated multi-triage AI device for FDA approval.
2m Dec 04, 2025
2m
Pharmaceutical Executive Daily: FDA's Agentic AI Deployment
In today’s Pharmaceutical Executive Daily, Regeneron launches a $150 million gene editing collaboration with Tessera Therapeutics, the FDA begins agency-wide deployment of new agentic AI tools, and a new report suggests Richard Pazdur is stepping down as director of CDER.
2m Dec 03, 2025
2m
Pharmaceutical Executive Daily: Lilly Reduces the Price of Zepbound
In today’s Pharmaceutical Executive Daily, Eli Lilly reduces the price of Zepbound single-dose vials for self-pay patients, a new report claims the FDA is planning changes to its vaccine approval process following assertions of COVID vaccine–related deaths, and Korea and Australia reorient their pharma launch strategies toward broader regional market opportunities.
2m Dec 02, 2025
2m
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
In today’s Pharmaceutical Executive Daily, Novo Nordisk files for FDA approval of a higher-dose Wegovy injectable using a priority review voucher, the US and UK agree to eliminate tariffs on pharmaceutical products, and CMS publishes major price cuts for 15 high-cost Medicare drugs under the latest IRA negotiation round.
2m Dec 01, 2025
2m
Pharmaceutical Executive Daily: Novartis Cuts 550 Jobs
In today’s Pharmaceutical Executive Daily, Novartis plans to eliminate 550 positions at a major Swiss site, the FDA authorizes the first gene therapy for adolescents and adults with spinal muscular atrophy, and industry experts weigh in on how next-generation CDMOs are evolving to meet rapid market change.
2m Nov 26, 2025
2m
Pharmaceutical Executive Daily: Moderna's $1.5 Billion Loan
In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes out a $1.5 billion loan to support its long-term growth plan, and Medicare moves closer to releasing negotiated prices for 15 widely used, high-cost medicines.
2m Nov 25, 2025
2m
Pharmaceutical Executive Daily: Tesaro and AnaptysBio's Legal Battle
In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship Pioneering and Valo Health announce major new collaborations, and why integrated direct-to-patient drug distribution is becoming a strategic imperative.
2m Nov 24, 2025
2m
Pharmaceutical Executive Daily: Novartis' North Carolina Manufacturing Hub
In today’s Pharmaceutical Executive Daily, learn how Abbott is acquiring Exact Sciences in a major diagnostics deal, Novartis is building a new manufacturing hub in North Carolina, and the FDA is rolling out a wide batch of drug approvals.
2m Nov 21, 2025
2m
Pharmaceutical Executive Daily: Moderna's $140 Million Manufacturing Investment
In today’s Pharmaceutical Executive Daily, learn how Moderna is expanding its manufacturing footprint in Massachusetts, GSK is advancing new research collaborations under the LTZ Fleming Initiative, and the FDA commissioner highlights how early and late movers can benefit from the National Priority Voucher program.
2m Nov 20, 2025
2m
Pharmaceutical Executive Daily: FDA's Approval of Epkinly
In today’s Pharmaceutical Executive Daily, learn how Novo Nordisk is launching an introductory offer for Wegovy and Ozempic, AbbVie and Genmab gain FDA approval for Epkinly in follicular lymphoma, and Johnson & Johnson announces a $3 billion definitive agreement to acquire Halda Therapeutics.
2m Nov 19, 2025
2m
Pharmaceutical Executive Daily: Novo Nordisk's Leadership Restructure
In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli Lilly, and the FDA launches its new Plausible Mechanism Pathway to accelerate drug development.
2m Nov 18, 2025
2m
Pharmaceutical Executive Daily: WeightWatchers Planning to Offer Wegovy Following Approval
In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA unveils a new Plausible Mechanism Pathway to accelerate drug reviews, and Ovid Therapeutics and Metagenomi share key third-quarter results and leadership changes.
2m Nov 13, 2025
2m
Pharmaceutical Executive Daily: Dr. Richard Pazdur Appointed as Director CDER
In today’s Pharmaceutical Executive Daily, Richard Pazdur is named director of FDA’s Center for Drug Evaluation and Research, Pfizer strengthens focus through strategic partnerships and spin-offs, and CMS launches a new initiative to reduce Medicaid drug costs.
2m Nov 13, 2025
2m
Pharmaceutical Executive Daily: AstraZeneca Becomes UK's Largest Stock
In today’s Pharmaceutical Executive Daily, AstraZeneca surpasses Shell to become the UK’s largest listed company, Basel intensifies efforts to attract international pharma executives, and HHS removes misleading safety warnings from menopausal hormone therapy labels.
2m Nov 12, 2025
2m
Pharmaceutical Executive Daily: Wegovy Shows Potential to Treat MASH Patients
In today’s Pharmaceutical Executive Daily, we report on new data showing Wegovy’s potential to reduce liver injury in patients with MASH, Eli Lilly’s latest strategic collaborations in gene therapy, and Novo Nordisk’s decision not to increase its acquisition offer for Metsera following Pfizer’s entry.
2m Nov 11, 2025
2m
Raising Biomarker Awareness
Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their treatment journey.
11m Nov 10, 2025
11m
Pharmaceutical Executive Daily: FDA Approves Darzalex Faspro
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma, the industry’s growing interest in direct-to-patient wholesale models, and the FDA’s expansion of its National Priority Voucher program to accelerate review of critical therapies.
2m Nov 10, 2025
2m
Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1's to TrumpRX
In today’s Pharmaceutical Executive Daily, we cover Eli Lilly and Novo Nordisk’s plans to bring their leading weight-loss medications to the TrumpRx platform, the State of Texas’ legal move to block Kenvue’s dividend payment, and the FDA approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma.
3m Nov 07, 2025
3m
Pharmaceutical Executive Daily: Novo Nordisk's Amended Acquisition Proposal
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are transforming pharma’s next frontier in commercial customer engagement.
3m Nov 06, 2025
3m
Pharmaceutical Executive Daily: Kimberly-Clark’s $48.7 Billion Acquisition of Kenvue
In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 billion investment to strengthen U.S. pharmaceutical distribution, and new industry collaborations advancing autoimmune and oncology research pipelines.
3m Nov 05, 2025
3m
Pharmaceutical Executive Daily: Pfizer Files Lawsuits Against Metsera and Novo Nordisk
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged intellectual property infringement, Eli Lilly’s $3 billion investment in a new Netherlands manufacturing site, and the latest wave of biotech partnerships and licensing agreements driving innovation.
3m Nov 04, 2025
3m
Pharmaceutical Executive Daily: George Tidmarsh Resigns from FDA
In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s plan to submit its oral GLP-1 candidate for FDA priority review, the departure of senior FDA official George Tidmarsh, and growing global venture capital investment in biopharma innovation.
3m Nov 03, 2025
3m
Pharmaceutical Executive Daily: Novo Nordisk's Unsolicited Acquisition Proposal
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F. Kennedy Jr., and AbbVie’s stronger 2025 profit outlook driven by immunology demand.
3m Oct 31, 2025
3m
Pharmaceutical Executive Daily: Thermo Fisher's $8.8 Billion Acquisition of Clario Holdings
In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli Lilly’s partnership with Walmart to launch retail pickup for its direct-to-consumer Zepbound program, and the FDA’s new draft guidance aimed at streamlining biosimilar development.
3m Oct 30, 2025
3m
Pharmaceutical Executive Daily: Lilly and NVIDIA Create AI Supercomputer
In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s partnership with NVIDIA to develop an AI supercomputer for drug discovery, a surge in biotech funding rounds and public offerings, and the FDA approval of Merck’s Winrevair for pulmonary arterial hypertension.
3m Oct 29, 2025
3m
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to expand its antibody-drug conjugate portfolio, and new guidance from the American College of Surgeons classifying obesity as a treatable condition.
3m Oct 28, 2025
3m
Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age
In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes, new research suggesting Ozempic may reduce biological age, and Novartis’ $12 billion merger agreement to acquire Avidity Biosciences.
3m Oct 27, 2025
3m
Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization
In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug commercialization, new funding momentum across rare disease R&D, and Eli Lilly’s definitive agreement to acquire Aderum Biotechnologies.
3m Oct 24, 2025
3m
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life Sciences’ acquisition of BPD Healthcare to strengthen its health system reach, and why clinical trial site satisfaction is becoming a key competitive differentiator for sponsors and CROs.
3m Oct 23, 2025
3m
Pharmaceutical Executive Daily: Novo Nordisk's Board Shake-Up
In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to reject a petition calling for Tylenol label changes, and industry insights from Bob Mauch on building a stronger, more resilient pharmaceutical supply chain.
3m Oct 22, 2025
3m
Pharmaceutical Executive Daily: Merck's $70 Billion Investment
In today’s Pharmaceutical Executive Daily, we cover Merck’s $70 billion expansion of U.S. operations, the FDA’s latest approvals for Novo Nordisk’s Rybelsus and Roche’s Gazyva, and a new digital health partnership between Amazon and WeightWatchers bringing prescription weight-loss drugs directly to consumers.
3m Oct 21, 2025
3m
Pharmaceutical Executive Daily: FDA's National Priority Voucher Program
In today’s Pharmaceutical Executive Daily, we cover the FDA’s creation of a new National Priority Voucher Program, the market reaction to President Trump’s remarks on GLP-1 drug prices, and how autonomous AI is transforming omnichannel marketing in pharma.
3m Oct 20, 2025
3m
Shifting Focus in Autoimmune Diseases
Artax Biopharma’s CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.
15m Oct 20, 2025
15m
Pharmaceutical Executive Daily: EMD Serono’s Agreement with US Government
In today’s Pharmaceutical Executive Daily, we explore how antibody-drug conjugate collaborations are moving beyond oncology into autoimmune diseases, EMD Serono’s agreement with the Trump administration to expand access to in vitro fertilization therapies, and how the obesity treatment market is evolving after GLP-1 dominance.
3m Oct 17, 2025
3m
Pharmaceutical Executive Daily: Rethinking Workforce Development
In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s growing investment in rare disease therapies, and emerging opportunities and challenges in psychiatric drug development.
3m Oct 16, 2025
3m
Pharmaceutical Executive Daily: Johnson & Johnson Separating Its Orthopedics Unit
In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopaedics division into a standalone company, the global implications of the Most Favored Nation drug pricing proposal, and strategies helping small biotechs reach market faster.
3m Oct 15, 2025
3m
Pharmaceutical Executive Daily: Direct-To-Consumer Trends
In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strategies, and reports of AstraZeneca reaching an agreement with the Trump administration.
3m Oct 14, 2025
3m
Advancing Neuroscience and Rare Disease Innovation
Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.
11m Oct 14, 2025
11m
Pharmaceutical Executive Daily: Policy Whiplash
In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic clarity amid policy whiplash, and Excellergy’s $70 million Series A launch to advance its trifunctional immunotherapy platform.
3m Oct 13, 2025
3m
Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug pricing proposal, and the FDA’s approval of Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma.
3m Oct 10, 2025
3m
Pharmaceutical Executive Daily: Why DSCSA Compliance is Only The Beginning
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCSA compliance is only the beginning of pharma supply chain modernization, and the agency’s approval of Jascayd for idiopathic pulmonary fibrosis.
3m Oct 09, 2025
3m